Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthRX vs LillyDirect Foundayo

HealthRX
Graded #8

Higher grade

vs+18.89999999999999
LillyDirect Foundayo
Graded #173

Lower grade

The verdict

HealthRX takes it — 86.1/100 to 67.2/100.

HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthRX +13
85
72
Dose & formulationHealthRX +31
90
59
Clinical oversightHealthRX +9
87
78
Labs & monitoringHealthRX +30
82
52
FulfillmentHealthRX +6
86
80
Contract termsHealthRX +30
85
55
HealthRX · left barLillyDirect Foundayo · right bar

The numbers

MetricHealthRXLillyDirect Foundayo
WeighScore86.1/10067.2/100
GradeBC
Scorecard rank#8#173
Semaglutide$189/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageNot publicly listedAll 50 states
Brand-name accessYesYes
Oral / sublingualYesYes
HealthRX

Graded #8 · B

Strengths

  • LegitScript-certified (#50087439) — a genuine, verifiable trust signal
  • Physician-supervised intake with licensed providers
  • Both molecules plus a rare oral GLP tablet option
  • Transparent flat monthly pricing, no insurance required

Where it loses points

  • Compounded semaglutide/tirzepatide is not FDA-approved
  • Some tiers are company-stated and the public site is thin
  • Brand Ozempic is a steep pass-through (~$1,299)
  • State count is not publicly listed
LillyDirect Foundayo

Graded #173 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard